A retrospective chart review of severe acute hyperlipidemic pancreatitis

Penta-therapy for severe acute hyperlipidemic pancreatitis: a retrospective chart review

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ISRCTN

Registry ID

ISRCTN11803209

Enrollment

Registered

2017-04-25

Start date

2017-02-02

Completion date

Unknown

Last updated

2019-09-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatitis Digestive System Pancreatitis

Interventions

This study is a retrospective study of patients who were hospitalised in the intensive care unit between January 2007 and December 2016. Participants are assigned to one of two groups based on the tre

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Aged 18 to 85 years old 2. Presented within 72 hours of the onset of pain 3. AP diagnosis made according to the Atlanta classification 4. Triglyceride levels of >1,000 mg/dL(11.3mmol/L),>500mg/dL(5.65mmol/L) with lipidic plasma and no other obvious cause of pancreatitis found for HL-SAP patients 5. Agree to participate and provide signed consent

Exclusion criteria

Exclusion criteria: 1. Flare-up of chronic pancreatitis 2. History of allergies to heparin or insulin 3. Disseminated intravascular coagulation or severe active bleeding 4. Respiratory failure, severe systemic circulatory failure, coma, or other life-threatening symptoms that were difficult to reverse and who were predicted to die within 24 hours (with full-fluid resuscitation and norepinephrine usage at a dose of 25 mg/ min, with a systolic blood pressure <90 mm Hg and serum pH values <7.0) 5. Patients who were delayed getting treatment because of some reason 6. Patients who presented with APACHE II score <3

Design outcomes

Primary

Measure	Time frame
1. Patient's condition is measured using the APACHE II score at date of admission 2. Organ function is measured using the SOFA score at date of admission 3. Pancreatitis severity is measured using the Ranson score at date of admission 4. Pancreatitis image level is measured using the CT severity index at date of admission 5. Laboratory findings is measured using serum biomarkers at date of admission and seven days	—

Measure

Time frame

1. Patient's condition is measured using the APACHE II score at date of admission 2. Organ function is measured using the SOFA score at date of admission 3. Pancreatitis severity is measured using the Ranson score at date of admission 4. Pancreatitis image level is measured using the CT severity index at date of admission 5. Laboratory findings is measured using serum biomarkers at date of admission and seven days

—

Secondary

Measure	Time frame
1. Rate of recurrence is measured using patient interviews during the study period 2. Overall mortality is measured by reviewing patient notes during the study period 3. Hospital length of stay is measured by reviewing patient notes during the study period 4. Operation rate is measured by reviewing patient notes during the study period 5. Local complications and systemic complications are measured byreviewing patient notes during the study period	—

Measure

Time frame

1. Rate of recurrence is measured using patient interviews during the study period 2. Overall mortality is measured by reviewing patient notes during the study period 3. Hospital length of stay is measured by reviewing patient notes during the study period 4. Operation rate is measured by reviewing patient notes during the study period 5. Local complications and systemic complications are measured byreviewing patient notes during the study period

—

Countries

China

Contacts

Public ContactRuilan Wang

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026